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Abstract 
Review on MCC, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: MCC1 




The MCC gene was discovered in 1991 due to its 
linkage with the APC gene (Kinzler et al., 1991; 
Nishisho et al., 1991). APC was quickly recognised 
as a key tumour suppressor gene and MCC is now 
also emerging as an important gene in cancer. MCC 
has multiple cellular functions and is frequently 
altered in colorectal cancer. 
Description 
Three isoforms of MCC have been identified; 
MCC-001 (17 exons), MCC-003 (19 exons) and 
MCC-011 (17 exons). MCC-001 and MCC-003 are 
known protein coding isoforms and MCC-011 is a 
putative protein coding isoform. 
Transcription 
In addition to the three protein coding transcripts, 
there are at least six non-coding transcripts (splice 
variants) of varying length. 
Protein 
Description 
MCC-001, 829 aa, known protein, predicted 93 kD; 
observed at 105 kD.  
MCC-003, 1019 aa, known protein, predicted 113 
kD.  
MCC-011, 766 aa, putative protein, predicted 86 
kD. 
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Expression 
Limited protein expression data are available but it 
appears that MCC expression is variable in 
different tissues.  
MCC protein is most highly expressed in the colon, 
heart, lung and brain (Pangon et al., unpublished). 
Localisation 
Cytoplasm, membrane cortex, nucleus. 
Function 
MCC is a tumour suppressor gene in colon and 
liver cancer. It regulates multiple cellular process  
in epithelial cells, such as proliferation (Matsumine 
et al., 1996), DNA damage response (Pangon et al., 
2010), lamellipodia formation (Pangon et al., 2012) 
and cell migration (Arnaud et al., 2009). MCC can 
suppress Wnt and NFkB signalling pathways 
(Bouwmeester et al., 2004; Fukuyama et al., 2008; 
Sigglekow et al., 2012) but the exact mechanisms 
remain poorly understood.  
The function of MCC itself can be regulated 
through post-transcriptional modifications, of 
which site-specific serine phosphorylation has been 




There are hundreds of SNPs in the coding region of 
MCC. Most are missense variants although short in-
frame indels or protein-truncating mutations have 
also been detected.  
No disease associations have been described for 
these germline variants or mutants.  
However, germline retrotransposition events have 
been identified in the MCC locus which ablate 
MCC expression and are associated with virally-
induced hepatocellular carcinoma (Shukla et al., 
2013). 
Somatic 
Despite its name, mutations of the MCC gene are 
found in only ~5% of colorectal cancers but MCC 
gene is silenced through promoter methylation in 
up to 50% of colorectal cancers (Kohonen-Corish et 
al., 2007; Fukuyama et al., 2008). For other cancers 
promoter methylation data are only available for 
lung cancer where MCC is not methylated 
(Poursoltan et al., 2012). MCC mutations have also 
been detected in 2-5% of other cancers, such as 
endometrial, melanoma, bladder urothelial, gastric, 
lung and prostate. Homozygous deletions have been 
detected in 2-4% of bladder urothelial carcinomas, 
ovarian serous cystadenocarcinomas, acute myeloid 
leukemias, prostate and gastric adenocarcinomas. 
MCC expression is downregulated in a subset of 
hepatocellular carcinomas possibly through several 
mechanisms, including LINE-1 insertion (Shukla et 
al., 2013) and targeting by oncogenic miRNA-494 
(Lim et al., 2013). 
Implicated in 
Sporadic colorectal cancer 
Oncogenesis 
Mouse experiments have shown that MCC is a 
tumour suppressor gene in colorectal cancer (Starr 
et al., 2009). In vitro experiments indicate that loss 
of MCC expression can impact on multiple 
signalling pathways but most strikingly on the 
activation of β-catenin directed transcription 
(Fukuyama et al., 2008). Aberrant activation of Wnt 
signalling is widely accepted as a major event in 
colorectal carcinogenesis and is mostly caused by 
APC mutations. It has been suggested that MCC 
silencing is also important in activating β-catenin, 
particularly in the context of the 'serrated neoplasia 
pathway' where APC mutations are less common 
but MCC methylation is frequent (Kohonen-Corish 
et al., 2007; Fukuyama et al., 2008; Li et al., 2013). 
Other possible tumour promoting mechanisms of 
MCC silencing include impaired DNA damage 
response to single-strand DNA breaks (Pangon et 
al., 2010). Site-specific phosphorylation of MCC 
regulates G2/M cell cycle arrest and loss of MCC is 
thus expected to promote proliferation of damaged 
cells. MCC also regulates lamellipodia formation in 
epithelial cells which suggests that MCC silencing 
could affect epithelial restitution in the colon 
(Pangon et al., 2012). 
Hepatocellular carcinoma 
Oncogenesis 
Loss of MCC expression in hepatocellular 
carcinoma is associated with aberrant activation of 
β-catenin (Shukla et al., 2013). MCC knockdown in 
vitro causes increased proliferation of 
hepatocellular cancer cells and is accompanied by 
increased G1/S transition (Lim et al., 2013). 
Acute myeloid leukemia 
Prognosis 
Loss of MCC expression has been studied in 
relation to chemotherapy responsiveness in acute 
myeloid leukemia. Lack of induction of MCC 
expression is associated with poorer responsiveness 
to cytarabine (Gamazon et al., 2013). 
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